Member Info for Moneymunch

All bodes well Porter, the share accumulation continues under the radar and no surprise, now we know Genflow have been invited to the prestigious JP Morgan HealthCare Conference. Get ready for a transformational and stellar 2026!!! Gl :-)

The J.P. Morgan 44th Annual Healthcare Conference for 2026 is scheduled for January 12-15, 2026, in San Francisco, California, primarily at the Westin St. Francis Hotel, focusing on pharma, biotech, medtech, AI in healthcare, and digital health, drawing major industry players, investors, and innovators for networking and deal-making. It's an invitation-only event, a key barometer for investor sentiment, with many announcements timed around it.

Key Details:

Dates: January 12-15, 2026.

Location: San Francisco, CA (Westin St. Francis Hotel).

Nature: Invitation-only, industry-leading investment symposium.

Attendees: Global industry leaders, emerging companies, investors, tech innovators.

Topics: Breakthrough therapies (oncology, neurology), AI in drug discovery, regulatory shifts, digital health, M&A trends.

Why It's Important:

It's the largest healthcare investment conference, influencing investor sentiment for the year.

Major licensing deals, pipeline updates, and strategic partnerships are often announced during this week.

Brilliant news Porter, and no more high profile you can get with Genflow well and truly in the Global Biotech spotlight and full investor focus, and no doubt Eric and co fully loaded with compelling positive efficacy data. Exciting times!!! Gl :-)

Genflow to Attend Healthcare Conference

GENFLOW BIOSCIENCES PLC

Released 07:00:09 11 December 2025

RNS Number : 0160L

Genflow Biosciences PLC

11 December 2025

Genflow Biosciences Plc

Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12-15, 2026, at the Westin St. Francis in San Francisco, California.

J.P. Morgan's Healthcare Conference is the sector's most influential global investment gathering, connecting industry leaders, high-growth innovators, and the investment community. Genflow's participation provides an opportunity to engage with potential partners, institutional investors, and pharmaceutical companies as the Company advances its gene-therapy pipeline targeting the SIRT6 longevity pathway.

About the 44th Annual J.P. Morgan Healthcare Conference

The 44th Annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together global industry leaders, emerging growth companies, technology innovators, and investors. More information is available on the conference website.

Dr. Eric Leire, CEO of Genflow, commented: "We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space."

Your 1.5m buy has just popped UP!!! Gl :-)

Maybe a bit of a tree shake earler to fill it??? :-)

It only dropped because of the 50k UT trade at 2.10p posted after hours yesterday, which caused the sp to close blue at 2.10p and then reverts to the correct closing price of 2p , which causes the sp to open in the red the following day. This happens all the time following an after hours UT trade, and in this current example, makes the chart with the step down from 2.1p to 2p, look perfectly primed and poised for the next UPward move as the next positive UPdate arrives and/or buying volumes increase. Gl :-)

They recently raised £440k in October via Eric and a consortium of long term Major Shareholders, a huge vote in confidence and commitment and I'm sure they wouldn't have parted with their hard earned cash if they didn't believe Genflow were on the brink of something big. The current sp performance certainly suggests the smart Money is accumulating and the free float is getting tighter and tighter, and with multiple potential material newsflow in the pipeline, including receipt confirmation of some of the outstanding £4.7m non-dilutive grant funding, as well as the the eagerly awaited efficacy results from the Dog Trial , where positive results will very likely see a game-changing lucrative licensing deal, the Genflow's upside potential and prospects look very exciting. Gla holders...Game changing news at anytime!!! :-)

9/10/25

Dr. Eric Leire, CEO of Genflow, commented: "We would like to express our sincere gratitude to our historical shareholders for their continued confidence and commitment to Genflow’s vision. Their ongoing support reflects a shared belief in our mission. With this additional capital, Genflow is able to deliver on our near-term objectives."

Looks like sub 2p is gone, UPward momentum in anticipation of multiple potential material newsflow, some of which could be game changing. Gla holders....Excitement building....On and UP!!! :-)

Pharma M&A Deals Surge to USD 82.6 Billion in Q2 2025 as Big Pharma Accelerates Acquisitions in Oncology, Rare Diseases & AI-Driven Drug Discovery

12-01-2025

Sub-Headline: Global pharmaceutical M&A deal value increased from USD 64.2 billion in Q2 2024 to USD 82.6 billion in Q2 2025, reflecting a strong 28.6% YoY growth, driven by strategic acquisitions in oncology, gene therapy, immunology, and AI-enabled drug development platforms.

Introduction

The M&A Trends in Pharma - Q2 2025 Market analysis reveals a high-momentum quarter, with pharmaceutical giants aggressively acquiring biotech innovators to strengthen clinical pipelines, expand therapeutic portfolios, and accelerate time-to-market for breakthrough therapies.

Key areas driving acquisition interest include:

• Oncology (ADC, IO, CAR-T, radiopharmaceuticals)

• Rare diseases & orphan drugs

• Gene therapy & RNA therapeutics

• AI drug discovery platforms

• Immunology & autoimmune diseases

• Digital-biotech & clinical trial technology

The return of high-value deals signals Big Pharma's need to offset patent cliffs and increase long-term revenue stability.

The global pharma industry entered 2025 with renewed investment strength as companies pursue pipeline diversification and innovation-led acquisitions.

"The pharma M&A landscape in Q2 2025 confirms a decisive shift toward oncology leadership, gene therapy, and AI-first drug discovery models. Big Pharma is aggressively pursuing acquisitions that offer long-term clinical and commercial durability."

The pharma M&A market in Q2 2025 is experiencing exceptional momentum, driven by oncology breakthroughs, high-value gene therapy assets, and AI-driven early-stage platforms. Companies investing in transformative, multi-modal biopharma technologies will lead next-generation therapeutic markets through 2030.

The calm before the storm??? A could of nice big buys 1.1m and 1.4m posted after hours yesterday, late reported from Friday's action with some chunky buys. The smart Money is obviously still accumulating for bigger and better things to come. Multiple potential material newsflow in the pipeline to add significant value!!! Gla holders:-)

Get UP there!!! ...Gla holders, they want your shares, Game changing news at anytime!!! On and UP!!! Ho ho ho :-)

A nice 1.4m buy at 1.74p, late reported from yesterday just popped UP!!! Gla holders, they want your shares...Game changing news at anytime!!! :-)

Finally, great news for Genflow!!! All budgets have been in limbo for months, and no doubt the reason for the delay in payment of the outstanding €4.7m non-dilutive grant funding. Gla holders....Game changing news at anytime!!! :-)

24th November 2025

Reuters

Belgian government reaches budget deal after months of talks

(Reuters) -The Belgian government on Monday reached ​an agreement on its budget ‌for next year after months of tense negotiations,‌ broadcaster VRT reported citing Prime Minister Bart De Wever.

De Wever earlier this month set a Christmas deadline ⁠for his ‌bickering five-party coalition to reach a deal, after ‍they continued to disagree on how to repair government finances.

Agreement was reached during ​marathon talks that started on Sunday ‌morning and went until early on Monday.

10th September 2025

BioWin launches call 47 for collaborative health innovation projects - BioWin https://share.google/IFsaHzM2cBANxtdfq

Lol, we're all friends here, and usually nothing goes UP in a straight line and if it does, it very often comes back down in a straight line and so the slight retrace is par for the course as we await the next UPdate from Eric and co. There’s plenty of material news that could drop including game changing news on the Dog Trial etc, but the delay in receipt confirmation for a tranche of the outstanding €4.7m hasn't helped the current performance. Belgium/Wallonia are currently in the process of finalising their Budget for the year ahead which has been delayed for multiple reasons, coalition Govt. and a rather large deficit, but the Prime Minister has stated the budget will be approved/ in place by Christmas. Genflow's reaffirmation in July, that the €4m grant is awaiting sign off , hopefully means that payment will be made just soon the budget is sorted and as Wallonia/BioWin since September 2025 are still encouraging applicants for non-dilutive grant funding, Genflow's €4m award should be well ahead in the process. Gla holders, multiple potential material newsflow in the pipeline. ;-)

The findings open the door to boosting the body’s natural repair mechanisms. Scientists could design medications that enhance or fine-tune Sirt6 function without relying on strict calorie restriction, which could help prevent or slow age-related diseases such as cancer, diabetes, cardiovascular issues, and frailty.

Because Sirt6 precisely regulates hydrogen sulfide (H2S) levels, drugs or interventions could aim to maintain H2S within an optimal range, avoiding the risks of excess or deficiency. This could improve wound healing, heart health, and brain function in older adults.

Moreover, H2S levels and Sirt6 activity could become measurable biomarkers to assess biological aging and tailor personalized interventions for age-related conditions.

The study was recently published in the peer-reviewed Proceedings of the National Academy of Sciences.

Latest compelling research on Sirt6's importance and panacea potential in longevity and disease prevention...all bodes well for Genflow’s strong patent protected cutting edge science...every chance Major Pharma will be doing their due- diligence. Gla holders...game changing news at anytime!!! ;-)

Research reveals key protein regulates molecule that slows aging, boosts healing - study

The study focused on a protein known for its role in longevity and disease prevention.

NOVEMBER 18,2025

The human body has a remarkable ability to protect itself from age-related decline, repair damage, support heart and brain health, and fend off common diseases through systems that keep its internal chemistry in balance.

Now, Israeli and American scientists have shed light on how one of these systems works, offering clues for extending healthy, active years later in life.

The study focused on a protein known for its role in longevity and disease prevention. Scientists found that it does more than protect against aging: it carefully regulates a molecule called hydrogen sulfide, which supports wound healing, cardiovascular health, and brain function.

While hydrogen sulfide levels naturally decline with age, this protein ensures that production remains within an optimal range, high enough to protect cells and tissues but not so high as to become harmful.

“This protein acts like the body’s internal version of calorie restriction,” said Prof. Haim Cohen, director of the Sagol Healthy Human Longevity Center at Bar-Ilan University. “It protects against age-related diseases and helps maintain the body’s natural balance as we grow older."

"It has one foot on the gas and the other on the brake, promoting hydrogen sulfide production when it’s beneficial but keeping it under control to prevent harm.”

Cohen led the study with PhD student Noga Touitou, in collaboration with the laboratory of Prof. Rafael de Cabo at the National Institute on Aging in Baltimore, Maryland.

The research builds on earlier studies showing that the protein can extend lifespan and shield against multiple age-related conditions. Until now, however, scientists have not fully understood how it achieves these effects.

The findings reveal that the key lies in precise regulation of hydrogen sulfide, rather than simply increasing levels, highlighting the importance of balance in healthy aging.

“Our findings show one of the body’s natural strategies for staying healthy during aging,” Cohen explained. “By revealing how this protein controls hydrogen sulfide production, we provide insight into how aging can be slowed and identify possible targets for therapies that help people stay healthier longer.”

This research represents the first comprehensive study of anti-aging mechanism in glaucoma by experiments in multiple mouse models that collectively encompass diverse aspects of glaucomatous pathology.

"Therapeutically targeting Sirt6 offers a promising new avenue for glaucoma treatment, especially for cases that do not respond to traditional treatments aimed at reducing eye pressure," said co-senior author Wenbo Zhang, professor at the Department of Ophthalmology and Visual Sciences at UTMB. "This could be a game-changer in how we approach this disease."

UTMB Study Identifies an Anti-Aging Protein as Key to Preventing Vision Loss in Glaucoma hTtps://share.google/X0h4m9NIzYyq9oTIA

10/4/25

Genflow Biosciences Launches New Ophthalmology Development Program

Signs MTA with Leading Ophthalmology Company

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is excited to announce the launch of a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma.

This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system.

Said Dr. Eric Leire, CEO of Genflow Biosciences: "We are thrilled to advance our ophthalmology program. The eye, as a closed and accessible compartment, presents an ideal target for gene therapy. More importantly, we believe that SIRT6 holds significant promise to transform the treatment landscape for corneal endothelial disorders and glaucoma."

Over 7 months since Genflow signed a Material Transfer Agreement with a leading Ophthamology Company for Sirt6 Gene Therapy for Glaucoma, and so potential game changing news at anytime, given Gene Therapy for eye disease is now an "emerging iinterest" for Lilly and other Major Pharma, and recent research on Sirt6 and Glaucoma concludes Sirt6 Gene Therapy could be a game changer for treating the disease. Gla holders ;-)

Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close in.

November 10, 2025

......

Andrew Adams, Lilly’s group vice-president of molecule discovery, said: “Ophthalmology is an emerging area of interest for Lilly. We are excited to partner with MeiraGTx to bring transformative treatments to patients around the world suffering from eye diseases, starting with AAV-AIPL1, which has shown the unprecedented ability to restore vision in children who were born legally blind.”

.....

Adams’ statement that ophthalmology represents an “emerging area of interest” for Lilly is supported by the money the company has recently spent in the area. last month, Lilly outlaid $261.7m to acquire Adverum Biotechnologies, a company developing an intravitreal gene therapy for the treatment of wet age-related macular degeneration (AMD). Combined with the MeiraGTx licensing deal, this means Lilly has spent more than half a billion dollars on gene therapies specifically in development for eye diseases.

This is not the only gene therapy area Lilly has targeted in 2025. In April, the big pharma company signed a licensing deal worth up to $1.4bn for Sangamo Therapeutics’ neurology-targeting gene therapy. In addition, Lilly acquired RNA-based gene therapy developer Rznomics in May 2025, and gene editing partner Verve Therapeutics for $1.3bn a month later.